抗新型冠状病毒药物致QT间期延长的文献复习及药学监护  

Anti-SARS-CoV-2 Drugs Induced QT Interval Prolongation: A Literature Review and Pharmaceutical Care

作　　者：朱素燕[1] 刘瑶[1] 陈春燕[1] 丁雄芳[1] 徐萍[1] ZHU Suyan;LIU Yao;CHEN Chunyan;DING Xiongfang;XU Ping(Department of Pharmacy,Ningbo NO.1 Hospital,Ningbo 315010,China)

机构地区：[1]宁波市第一医院药学部,浙江宁波315010

出　　处：《中国现代应用药学》2020年第5期560-563,共4页Chinese Journal of Modern Applied Pharmacy

摘　　要：本文对新型冠状病毒肺炎患者临床用药方案涉及的抗病毒药物致QT间期延长的文献报道情况进行复习。根据目前文献复习结果可知,洛匹那韦/利托那韦和磷酸氯喹存在引起QT间期延长进而引发尖端扭转型室速的潜在风险。在新型冠状病毒肺炎患者中使用此类药物需关注由此带来的用药风险,熟悉临床上常用的可引起QT间期延长的药物,提高识别患者QT间期延长的易感因素和药物相互作用的能力,重视心电图、电解质管理来预防临床潜在的药物致急性心律失常事件,以降低新型冠状病毒肺炎患者的药物不良反应,避免药源性损害。The literature of QT interval prolongation caused by antiviral drugs of clinical regimens or clinical trial protocols in Corona Virus Disease 2019(COVID-2019) patients was reviewed. According to the results of literature review, lopinavir/ritonavir and chloroquine have the potential risk of drug-induced long QT syndrome. In COVID-2019 patients, medication risk of drug-induced long QT syndrome should be concerned. The clinician and pharmacists should be familiar with the type of drugs that can cause QT interval prolongation, improve the ability to identify the factors of QT interval prolongation and drug interactions in patients, pay attention to ECG monitoring and electrolyte management to prevent clinical potential drug induced acute arrhythmia events and reduce adverse drug events in COVID-2019 patients.

关 键 词：新型冠状病毒肺炎 洛匹那韦/利托那韦 氯喹 QT间期延长 药物相互作用 药学监护 

分 类 号：R969.3[医药卫生—药理学]